January 23, 2023 02:48 PM EST
Pharma
FDA+
Marketing

Ad­vo­ca­cy group ac­cus­es No­vo Nordisk of vi­o­lat­ing FDA's 'fair bal­ance' ad­ver­tis­ing rules

Nicole DeFeudis

Editor

A non­prof­it ad­vo­ca­cy group has filed a com­plaint with the FDA ac­cus­ing No­vo Nordisk of lin­ing up pro­mo­tion­al ma­te­r­i­al for its weight loss drug We­govy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times